Developer docs
API playgroundTry for free, no card

Search company profiles

Tulavi Therapeutics

Full company profile

uuid0000haa

Namestring
Tulavi Therapeutics
Legal namestring
Tulavi Therapeutics, Inc.
Websiteurl
tulavi.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Tulavi Therapeutics is a privately held medical device company headquartered in Los Gatos, California that develops the allay™ Hydrogel Cap, the first and only fully absorbable technology FDA-cleared specifically to reduce the risk of symptomatic neuroma formation following peripheral nerve transection. The company was launched in 2018 as a portfolio company of Incept LLC, a hands-on medical technology accelerator that has launched 27 companies over 26 years, and the device is built on Incept's proprietary Adaptive Hydrogel Platform, which has been deployed in over 5 million patients worldwide across multiple specialties.

The allay™ Hydrogel Cap is a fully absorbable, sutureless, in situ forming hydrogel device that conforms to the transected nerve end, creating a non-compressive, hydrophilic barrier that remains in place for approximately 8 months to block axonal escape during the critical period of neuroma formation, after which it hydrolyzes and is absorbed. The product is offered in Small Nerve Set (1-4mm, Model TL-5515-1) and Large Nerve Set (5-7mm, Model TL-5515-2) variants, with single-use delivery tips (Model TL-7627) as an accessory, and the company cites six preclinical studies with n>170 subjects showing no neuroma formation. In October 2025 the FDA indication was expanded to patients weighing 25 kg and above, and in December 2025 the first peer-reviewed clinical data was published in Plastic and Reconstructive Surgery Global Open.

Tulavi monetizes through single-use hardware sales of the allay™ cap to surgeons and hospitals, combining direct enterprise sales with two distribution channels: a January 2026 Vizient Innovative Technology contract providing access to a network representing over $140 billion in annual purchasing volume, and a July 2025 channel partnership with Veterans Healthcare Supply Solutions (VHSS) for VA hospitals and Military Treatment Facilities via the ECAT federal procurement system. The company has raised approximately $5.84 million in disclosed funding across 2018-2021 and is led by CEO Josh Vose (MD, MBA) and Chairman & Co-Founder Fred Khosravi, with board representation from Incept LLC, Delos Capital, and Ascension Ventures.

Short descriptiontext

Tulavi Therapeutics is a privately held medical device company that develops the allay Hydrogel Cap, the first FDA-cleared fully absorbable technology to reduce symptomatic neuroma formation, sold to surgeons and hospitals performing peripheral nerve procedures across the U.S.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Gatos, United States
HQ citystring
Los Gatos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve surgery, medical device manufacturing, hydrogel nerve cap, neuroma prevention devices, surgical nerve protection
Industry2 codes
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Surgical medical devices — peripheral nerve protection
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1allay™ Hydrogel Cap Sales
TypeHardware Sales
Description

Medical device sales model where the allay™ Hydrogel Cap is sold as a single-use surgical device to hospitals, surgeons, and federal healthcare facilities. Revenue generated from product sales through direct sales team, channel partners (VHSS), and GPO contracts (Vizient). Single-use disposable device with per-procedure revenue generation.

tulavi.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1allay™ Hydrogel Cap
Description

The first and only fully absorbable technology specifically indicated to reduce the risk of symptomatic neuroma formation. A novel, fully absorbable, sutureless surgical device that provides a perfectly conforming barrier to the injured nerve.

tulavi.com
Core offering1 text field

Tulavi Therapeutics develops and commercializes the allay™ Hydrogel Cap, a fully absorbable, sutureless surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The device forms an in situ hydrogel barrier that conforms to the nerve end, remains in place for approximately eight months, and is sold in small and large nerve size variants to orthopedic and plastic surgeons as well as federal healthcare facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • No neuroma formation demonstrated across 6 preclinical studies with n>170 subjects
+3 more records
Product overview1 text field

Tulavi Therapeutics offers a single core product platform — the allay™ Hydrogel Cap — with specialized configurations for different nerve sizes. The portfolio consists of the main allay™ Hydrogel Cap device (a fully absorbable, sutureless hydrogel barrier for peripheral nerve protection), available in Small Nerve Set (1-4mm, Model TL-5515-1) and Large Nerve Set (5-7mm, Model TL-5515-2) variants, plus Additional Delivery Tips (Model TL-7627) as an accessory. The technology is built on a proprietary Adaptive Hydrogel Platform with demonstrated safety in over 5 million patients worldwide, specifically engineered for nerve healing applications.

Product and service4 records
1allay™ Hydrogel Cap
CategoryPeripheral nerve protection / surgical implant
Description

A fully absorbable, sutureless, in situ forming hydrogel surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The cap remains in place for approximately 8 months, providing a non-compressive, hydrophilic, flexible barrier that blocks axonal escape during the critical period of neuroma development. Indicated for surgeons performing peripheral nerve procedures in amputations, neuroma excisions, and soft tissue repair.

2allay™ Small Nerve Set (Model # TL-5515-1)
CategoryPeripheral nerve protection / surgical implant
Description

Size-specific configuration of the allay™ Hydrogel Cap designed for small peripheral nerves in 1, 2, 3, and 4 mm diameters (Model # TL-5515-1). Enables treatment of multiple smaller nerves across a broad range of sizes in a single procedure.

3allay™ Large Nerve Set (Model # TL-5515-2)
CategoryPeripheral nerve protection / surgical implant
Description

Size-specific configuration of the allay™ Hydrogel Cap designed for larger peripheral nerves in 5, 6, and 7 mm diameters (Model # TL-5515-2). Enables treatment of multiple larger nerves across a broad range of sizes in a single procedure.

4allay™ Additional Delivery Tips (Model # TL-7627)
CategorySurgical device accessory
Description

Single-use delivery tips for the allay™ Hydrogel Cap system, sold as a separately packaged accessory (Model # TL-7627). One box contains six packages, each with one single-use delivery tip.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-01-13
Description

Innovative Technology contract awarded to allay™ Hydrogel Cap. Vizient is the nation's largest provider-driven healthcare performance improvement company representing over $140 billion in annual purchasing volume. The contract signifies unique qualities that potentially bring improvement to healthcare and enables access to Vizient's diverse client base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-23
Description

Partnership to distribute the allay™ Hydrogel Cap to U.S. Department of Veterans Affairs (VA) hospitals and Military Treatment Facilities nationwide. This partnership brings Tulavi's innovative technology to the forefront of veteran care, expanding access to treatment for peripheral nerve injuries. The allay™ Hydrogel Cap is now available to federal healthcare providers via the ECAT through VHSS.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market-leading peripheral nerve repair company with the Avance nerve allograft platform, dominating the same surgical specialty (peripheral nerve surgeons performing neuroma management, amputation, and nerve gap procedures) that Tulavi targets with allay™.

TypeEmerging player
Description

Early-stage company developing nerve regeneration and neuroma prevention technologies targeting the same peripheral nerve surgery market as Tulavi's allay™ Hydrogel Cap.

TypeBroad incumbent
Description

Through its surgical solutions portfolio (including legacy Synovis Micro Companies Alliance products), Baxter competes in the peripheral nerve repair and microsurgery space served by Tulavi.

4RTI Surgical
TypeBroad incumbent
Description

Medical device company offering surgical implants including nerve repair solutions that compete for the same hospital procurement budgets in peripheral nerve procedures.

5Cook Medical
TypeDirect peer
Description

Manufactures nerve repair and surgical devices including nerve conduits, supplying the same peripheral nerve surgeon specialty with overlapping neuroma management solutions.

TypeEmerging player
Description

Develops NEUROCAP, a biodegradable nerve cap device for symptomatic neuroma prevention — a directly comparable product concept to Tulavi's allay™ Hydrogel Cap, competing for the same surgical indication and customer base.

TypeBroad incumbent
Description

Large diversified medical device company with a peripheral nerve repair portfolio including NeuraGen nerve guide and related products, serving overlapping surgical customers across reconstructive and orthopedic surgery.

TypeBroad incumbent
Description

Major medical device incumbent with broad surgical and orthopedic portfolios that compete for the same hospital budgets and OR shelf space as Tulavi's allay™ product.

TypeBroad incumbent
Description

Global medical device leader with neurostimulation and surgical portfolios that overlap the peripheral nerve treatment space and compete for hospital formulary inclusion in the same accounts Tulavi targets.

10Collagen Solutions
TypeOthers
Description

Supplier of collagen-based biomaterials used in nerve repair devices and surgical applications, adjacent to Tulavi's hydrogel platform as an enabling technology provider in the same surgical ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tulavi Therapeutics

Surgical medical devices — peripheral nerve protectiontulavi.com

Tulavi Therapeutics is a privately held medical device company that develops the allay Hydrogel Cap, the first FDA-cleared fully absorbable technology to reduce symptomatic neuroma formation, sold to surgeons and hospitals performing peripheral nerve procedures across the U.S.

What Tulavi Therapeutics does

Tulavi Therapeutics is a privately held medical device company headquartered in Los Gatos, California that develops the allay™ Hydrogel Cap, the first and only fully absorbable technology FDA-cleared specifically to reduce the risk of symptomatic neuroma formation following peripheral nerve transection. The company was launched in 2018 as a portfolio company of Incept LLC, a hands-on medical technology accelerator that has launched 27 companies over 26 years, and the device is built on Incept's proprietary Adaptive Hydrogel Platform, which has been deployed in over 5 million patients worldwide across multiple specialties.

The allay™ Hydrogel Cap is a fully absorbable, sutureless, in situ forming hydrogel device that conforms to the transected nerve end, creating a non-compressive, hydrophilic barrier that remains in place for approximately 8 months to block axonal escape during the critical period of neuroma formation, after which it hydrolyzes and is absorbed. The product is offered in Small Nerve Set (1-4mm, Model TL-5515-1) and Large Nerve Set (5-7mm, Model TL-5515-2) variants, with single-use delivery tips (Model TL-7627) as an accessory, and the company cites six preclinical studies with n>170 subjects showing no neuroma formation. In October 2025 the FDA indication was expanded to patients weighing 25 kg and above, and in December 2025 the first peer-reviewed clinical data was published in Plastic and Reconstructive Surgery Global Open.

Tulavi monetizes through single-use hardware sales of the allay™ cap to surgeons and hospitals, combining direct enterprise sales with two distribution channels: a January 2026 Vizient Innovative Technology contract providing access to a network representing over $140 billion in annual purchasing volume, and a July 2025 channel partnership with Veterans Healthcare Supply Solutions (VHSS) for VA hospitals and Military Treatment Facilities via the ECAT federal procurement system. The company has raised approximately $5.84 million in disclosed funding across 2018-2021 and is led by CEO Josh Vose (MD, MBA) and Chairman & Co-Founder Fred Khosravi, with board representation from Incept LLC, Delos Capital, and Ascension Ventures.

Tulavi Therapeutics firmographics

Firmographics
Name
Tulavi Therapeutics
Legal name
Tulavi Therapeutics, Inc.
Website
https://tulavi.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Tulavi Therapeutics is a privately held medical device company that develops the allay Hydrogel Cap, the first FDA-cleared fully absorbable technology to reduce symptomatic neuroma formation, sold to surgeons and hospitals performing peripheral nerve procedures across the U.S.
Ownership category
akta.pro rank

Tulavi Therapeutics industry classification

Industry
Product category
Surgical medical devices — peripheral nerve protection
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Peripheral nerve surgery
  • Medical device manufacturing
  • Hydrogel nerve cap
  • Neuroma prevention devices
  • Surgical nerve protection

Where Tulavi Therapeutics is headquartered

Location

Headquarters

HQ city
Los Gatos
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tulavi Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations

Revenue model

  1. allay™ Hydrogel Cap Sales: Medical device sales model where the allay™ Hydrogel Cap is sold as a single-use surgical device to hospitals, surgeons, and federal healthcare facilities. Revenue generated from product sales through direct sales team, channel partners (VHSS), and GPO contracts (Vizient). Single-use disposable device with per-procedure revenue generation.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Tulavi Therapeutics product offering

Product offering

Core offering

Tulavi Therapeutics develops and commercializes the allay™ Hydrogel Cap, a fully absorbable, sutureless surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The device forms an in situ hydrogel barrier that conforms to the nerve end, remains in place for approximately eight months, and is sold in small and large nerve size variants to orthopedic and plastic surgeons as well as federal healthcare facilities.

Product overview

Tulavi Therapeutics offers a single core product platform — the allay™ Hydrogel Cap — with specialized configurations for different nerve sizes. The portfolio consists of the main allay™ Hydrogel Cap device (a fully absorbable, sutureless hydrogel barrier for peripheral nerve protection), available in Small Nerve Set (1-4mm, Model TL-5515-1) and Large Nerve Set (5-7mm, Model TL-5515-2) variants, plus Additional Delivery Tips (Model TL-7627) as an accessory. The technology is built on a proprietary Adaptive Hydrogel Platform with demonstrated safety in over 5 million patients worldwide, specifically engineered for nerve healing applications.

Differentiator

Problem solved

Functional benefit

Brands

  • allay™ Hydrogel Cap: The first and only fully absorbable technology specifically indicated to reduce the risk of symptomatic neuroma formation. A novel, fully absorbable, sutureless surgical device that provides a perfectly conforming barrier to the injured nerve.

Products and services

  • allay™ Hydrogel Cap A fully absorbable, sutureless, in situ forming hydrogel surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The cap remains in place for approximately 8 months, providing a non-compressive, hydrophilic, flexible barrier that blocks axonal escape during the critical period of neuroma development. Indicated for surgeons performing peripheral nerve procedures in amputations, neuroma excisions, and soft tissue repair.
  • allay™ Small Nerve Set (Model # TL-5515-1) Size-specific configuration of the allay™ Hydrogel Cap designed for small peripheral nerves in 1, 2, 3, and 4 mm diameters (Model # TL-5515-1). Enables treatment of multiple smaller nerves across a broad range of sizes in a single procedure.
  • allay™ Large Nerve Set (Model # TL-5515-2) Size-specific configuration of the allay™ Hydrogel Cap designed for larger peripheral nerves in 5, 6, and 7 mm diameters (Model # TL-5515-2). Enables treatment of multiple larger nerves across a broad range of sizes in a single procedure.
  • allay™ Additional Delivery Tips (Model # TL-7627) Single-use delivery tips for the allay™ Hydrogel Cap system, sold as a separately packaged accessory (Model # TL-7627). One box contains six packages, each with one single-use delivery tip.

Quantifiable outcome

  • No neuroma formation demonstrated across 6 preclinical studies with n>170 subjects
  • +3 more outcomes

Companies that use Tulavi Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Tulavi Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Tulavi Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • VizientcoreGTM or Marketing Partner · 13 January 2026Innovative Technology contract awarded to allay™ Hydrogel Cap. Vizient is the nation's largest provider-driven healthcare performance improvement company representing over $140 billion in annual purchasing volume. The contract signifies unique qualities that potentially bring improvement to healthcare and enables access to Vizient's diverse client base including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers.
  • Veterans Healthcare Supply Solutions (VHSS)coreChannel Partner/ Reseller/ Distributor · 23 July 2025Partnership to distribute the allay™ Hydrogel Cap to U.S. Department of Veterans Affairs (VA) hospitals and Military Treatment Facilities nationwide. This partnership brings Tulavi's innovative technology to the forefront of veteran care, expanding access to treatment for peripheral nerve injuries. The allay™ Hydrogel Cap is now available to federal healthcare providers via the ECAT through VHSS.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Tulavi Therapeutics competitors and assessment

Company assessment

Direct peers

  • Axogen: Market-leading peripheral nerve repair company with the Avance nerve allograft platform, dominating the same surgical specialty (peripheral nerve surgeons performing neuroma management, amputation, and nerve gap procedures) that Tulavi targets with allay™.
  • Cook Medical: Manufactures nerve repair and surgical devices including nerve conduits, supplying the same peripheral nerve surgeon specialty with overlapping neuroma management solutions.

Emerging players

  • Renerve: Early-stage company developing nerve regeneration and neuroma prevention technologies targeting the same peripheral nerve surgery market as Tulavi's allay™ Hydrogel Cap.
  • Polyganics: Develops NEUROCAP, a biodegradable nerve cap device for symptomatic neuroma prevention — a directly comparable product concept to Tulavi's allay™ Hydrogel Cap, competing for the same surgical indication and customer base.

Broad incumbents

  • Baxter International: Through its surgical solutions portfolio (including legacy Synovis Micro Companies Alliance products), Baxter competes in the peripheral nerve repair and microsurgery space served by Tulavi.
  • RTI Surgical: Medical device company offering surgical implants including nerve repair solutions that compete for the same hospital procurement budgets in peripheral nerve procedures.
  • Integra LifeSciences: Large diversified medical device company with a peripheral nerve repair portfolio including NeuraGen nerve guide and related products, serving overlapping surgical customers across reconstructive and orthopedic surgery.
  • Stryker: Major medical device incumbent with broad surgical and orthopedic portfolios that compete for the same hospital budgets and OR shelf space as Tulavi's allay™ product.
  • Medtronic: Global medical device leader with neurostimulation and surgical portfolios that overlap the peripheral nerve treatment space and compete for hospital formulary inclusion in the same accounts Tulavi targets.

Others

  • Collagen Solutions: Supplier of collagen-based biomaterials used in nerve repair devices and surgical applications, adjacent to Tulavi's hydrogel platform as an enabling technology provider in the same surgical ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Tulavi Therapeutics social profiles

Digital presence

Tulavi Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tulavi Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Tulavi Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tulavi Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tulavi Therapeutics

What does Tulavi Therapeutics do?

Tulavi Therapeutics develops and commercializes the allay™ Hydrogel Cap, a fully absorbable, sutureless surgical implant designed to protect transected peripheral nerves and reduce the risk of symptomatic neuroma formation. The device forms an in situ hydrogel barrier that conforms to the nerve end, remains in place for approximately eight months, and is sold in small and large nerve size variants to orthopedic and plastic surgeons as well as federal healthcare facilities.

Is Tulavi Therapeutics a public or private company?

Tulavi Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tulavi Therapeutics founded?

Tulavi Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Tulavi Therapeutics based?

Tulavi Therapeutics is headquartered in Los Gatos, United States, in the North America region.

How does Tulavi Therapeutics make money?

One revenue line is on record: allay™ Hydrogel Cap Sales.

Who are Tulavi Therapeutics's main competitors?

Direct peers on record are Axogen and Cook Medical. Emerging players are Renerve and Polyganics. Broad incumbents are Baxter International, RTI Surgical, Integra LifeSciences, Stryker and Medtronic. Collagen Solutions is listed as an others.

Does Tulavi Therapeutics have an API?

No public API is recorded for Tulavi Therapeutics.

What industry is Tulavi Therapeutics in?

Tulavi Therapeutics's product category is Surgical medical devices — peripheral nerve protection. Its primary akta.pro industry code is HLAHAEAD, Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts), with a secondary code of HLAHALAA, Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooTulavi Therapeutics Awarded Breakthrough Technology Designation for Synthetic Implantable Products with Premier, Inc.Tulavi Therapeutics received a Breakthrough Technology Designation and a national group purchasing agreement with Premier, Inc. for its allay Hydrogel Cap, effective September 15, 2026. The device is a fully resorbable, in situ forming medical device to reduce symptomatic neuroma formation. The company cites 600,000 amputations and 1.9 million peripheral nerve surgeries annually in the U.S.PR NewswireTulavi Therapeutics Awarded Breakthrough Technology Designation for Synthetic Implantable Products with Premier, Inc.Tulavi Therapeutics received a Breakthrough Technology Designation and a national group purchasing agreement with Premier, Inc. for its allay Hydrogel Cap, effective September 15, 2026. The device is the first fully resorbable, in situ forming medical device to reduce symptomatic neuroma formation. The agreement aims to expand access for patients and providers.Current PublishingNew tech helps Carmel resident stop planning around painCarmel resident Olivia Sandlin underwent a below-the-knee amputation on March 23, becoming the first patient in Indiana to receive an allay Hydrogel Cap by Tulavi Therapeutics during the procedure. The surgery was performed by a team from OrthoIndy and Indiana Hand to Shoulder Center using nerve-management techniques to prevent painful neuromas and reduce phantom limb pain. Three months post-surgery, Sandlin reports significant pain reduction and has begun using a temporary prosthesis.WIBC 93.1 FMIndy Doctors Debut Hydrogel Technology to Block Amputee PainA team of specialists from OrthoIndy and the Indiana Hand to Shoulder Center utilized Tulavi Therapeutics' allay™ Hydrogel Cap during an amputation procedure in Indiana, aiming to prevent phantom limb pain. The hydrogel technology aims to reduce the formation of painful neuromas after nerve severing, with initial results showing promise in eliminating sensitivity in treated areas. The success highlights advancements in medical treatment for amputees, enhancing their recovery prospects.PR NewswireTulavi Therapeutics Receives Innovative Technology Contract from Vizient for the allay™ Hydrogel CapTulavi Therapeutics has been awarded an Innovative Technology contract from Vizient for its allay™ Hydrogel Cap, a surgical device designed to support nerve healing and reduce symptomatic neuroma formation following peripheral nerve injuries or amputations. The contract was granted following review by hospital experts on Vizient's client-led councils, which evaluate technologies for their potential to enhance clinical care, patient safety, and healthcare operations, with Vizient representing over $140 billion in annual purchasing volume. The allay™ Hydrogel Cap is built on a proprietary hydrogel platform that has been safely used in over 5 million patients worldwide and remains in place for approximately eight months after deployment.PR NewswireTulavi Therapeutics Expands Indication for allay™ Hydrogel Cap to Smaller Patients, 25 kg and AboveTulavi Therapeutics announced an expanded indication for its allay™ Hydrogel Cap, extending use to patients weighing 25 kilograms and above, previously limited to larger patients. The device is a fully absorbable, sutureless hydrogel that provides a protective barrier to transected nerves, supporting recovery while reducing the risk of symptomatic neuroma formation for up to eight months. This expansion reflects the company's mission to broaden access to a population that suffers similar injuries as older, larger individuals and addresses an unmet need in peripheral nerve surgery.PR NewswireTulavi Therapeutics Selected to Exhibit the allay™ Hydrogel Cap at Vizient Innovative Technology ExchangeTulavi Therapeutics has been selected to exhibit its allay™ Hydrogel Cap, a sutureless surgical device designed to protect transected nerves and reduce symptomatic neuroma formation, at the Vizient Innovative Technology Exchange on September 17 in Las Vegas. The device is built on a proprietary hydrogel platform that has been safely used in over 5 million patients worldwide and remains in place for approximately eight months post-deployment. The annual exchange offers selected suppliers the opportunity to demonstrate products to supply chain and clinical leaders from Vizient's hospital clients, which include a significant portion of U.S. healthcare facilities.PR NewswireTulavi and VHSS Partner to Bring Groundbreaking Surgical Nerve Treatment to Veterans Impacted by Amputations and Traumatic InjuriesTulavi Therapeutics has partnered with Veterans Healthcare Supply Solutions (VHSS) to distribute its allay™ Hydrogel Cap—a novel, fully absorbable, sutureless medical device for peripheral nerve protection—to U.S. Department of Veterans Affairs hospitals and Military Treatment Facilities nationwide. The device, designed to reduce neuroma formation and chronic nerve pain in amputees and those with traumatic nerve injuries, provides a conforming protective barrier for injured nerves and remains in place for approximately eight months. More than 60,000 U.S. veterans are living with limb loss, and countless others have sustained traumatic peripheral nerve injuries that can significantly impair mobility, prosthetic use, and quality of life.FierceBiotechFDA clears surgical hydrogel nerve cap for preventing phantom limb pain in amputeesTulavi Therapeutics has received de novo clearance from the FDA for its Allay nerve cap system, which is designed to help reduce phantom limb pain in amputees. The system encases severed nerves in a hydrogel that prevents the formation of neuromas, which are the leading cause of residual pain among amputees. This development could significantly impact the management of post-amputation pain, as current treatments typically involve surgical intervention.SecSEC FORM DTulavi Therapeutics, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b). The company disclosed a total offering amount of $1,000,000 USD and reported that nine investors have already participated in the offering.